At a glance
- Originator Biogen
- Developer Biogen; Merck & Co
- Class Antiasthmatics
- Mechanism of Action Integrin alpha4beta1 antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Asthma
Most Recent Events
- 12 Oct 1999 No-Development-Reported for Asthma in USA (Unknown route)
- 04 Dec 1997 Merck & Co. is a licensee for BIO 1272
- 16 May 1997 Preclinical development for Asthma in USA (Unknown route)